Is Bayer CropSci. overvalued or undervalued?

As of 17 October 2025, Bayer CropScience's valuation grade has moved from very expensive to expensive, indicating a slight improvement but still reflecting a high valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 38.24, an EV to EBITDA of 30.04, and a Price to Book Value of 7.95, all of which suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Bayer CropScience's PE ratio is higher than UPL's 37.91 and BASF India's 47.93, which are both classified as attractive. The PEG ratio stands at 0.00, indicating no growth expectations factored into the price, which is concerning. Recent stock performance shows that Bayer has underperformed against the Sensex, with a year-to-date return of -9.24% compared to the Sensex's 7.44%, reinforcing the notion that the stock may not be a favorable investment at its current valuation.